Delcath Systems (NASDAQ:DCTH) Announces Quarterly Earnings Results

Delcath Systems (NASDAQ:DCTH) issued its quarterly earnings results on Thursday. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.07, FiscalAI reports. Delcath Systems had a return on equity of 0.51% and a net margin of 0.62%.The company had revenue of $24.99 million during the quarter, compared to the consensus estimate of $23.51 million.

Here are the key takeaways from Delcath Systems’ conference call:

• Q1 operational momentum: the company activated 4 centers, reported record new patient starts, has 29 REMS‑certified sites and is modifying its activation goal to 37 centers by year‑end (40 by Q1 2027), reflecting broad commercial interest.
• Strong topline and guidance: Q1 revenue rose to $25.0M (vs $19.8M LY), ending cash of $89.3M, and management reiterated at least $100M revenue for 2026 with expected positive adjusted EBITDA for the remainder of the year.
• Clinical programs progressing but paced slowly: the metastatic CRC trial has 13 active screening sites with 7 patients enrolled (target 26 sites by year‑end; interim readout late 2027) and the metastatic breast program has 4 sites active with a target of 15 by late 2026, so readouts remain long‑dated and enrollment is ramping.
• CHOPIN data driving adoption: publication of the CHOPIN results in The Lancet Oncology (combination HEPZATO + immunotherapy showing ~76% response and survival separation) is cited as a key factor changing prescribing patterns and motivating many new sites to adopt a CHOPIN‑like protocol.

Delcath Systems Price Performance

NASDAQ DCTH traded up $0.24 during mid-day trading on Friday, hitting $11.48. The company’s stock had a trading volume of 569,665 shares, compared to its average volume of 339,366. Delcath Systems has a 52-week low of $8.12 and a 52-week high of $18.23. The stock’s fifty day simple moving average is $9.86 and its two-hundred day simple moving average is $9.82. The firm has a market capitalization of $395.60 million, a P/E ratio of 1,148.00 and a beta of 0.54.

Analyst Upgrades and Downgrades

DCTH has been the subject of several analyst reports. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Delcath Systems in a research note on Friday, January 9th. BTIG Research lowered their price target on Delcath Systems from $23.00 to $19.00 and set a “buy” rating for the company in a report on Thursday, February 26th. Wall Street Zen downgraded shares of Delcath Systems from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Finally, Evercore set a $27.00 price objective on shares of Delcath Systems in a report on Thursday, February 26th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $22.50.

Institutional Investors Weigh In On Delcath Systems

Several large investors have recently made changes to their positions in DCTH. Millennium Management LLC lifted its holdings in shares of Delcath Systems by 34.1% during the 1st quarter. Millennium Management LLC now owns 422,066 shares of the company’s stock valued at $5,373,000 after acquiring an additional 107,391 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in Delcath Systems by 58.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 123,487 shares of the company’s stock worth $1,572,000 after purchasing an additional 45,695 shares during the period. JPMorgan Chase & Co. increased its holdings in Delcath Systems by 229.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 168,245 shares of the company’s stock valued at $2,288,000 after purchasing an additional 117,118 shares in the last quarter. Legal & General Group Plc purchased a new position in Delcath Systems in the second quarter valued at about $46,000. Finally, Rhumbline Advisers purchased a new position in Delcath Systems in the second quarter valued at about $586,000. Institutional investors and hedge funds own 61.12% of the company’s stock.

Delcath Systems Company Profile

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.